CMS published the Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule (CMS-1850-P) on July 7, 2026. While hospital outpatient departments are the primary targets, physician practices that operate under HOPD billing arrangements, participate in 340B programs through affiliated entities, or bill imaging at off-campus provider-based departments will face material reimbursement consequences if this rule is finalized as proposed. The comment deadline is August 31, 2026 — 31 days from today.
The single most consequential provision cuts 340B-acquired drug reimbursement from ASP plus 6% to ASP minus 33.4% — a near-40-percentage-point swing. CMS bases this on survey data showing that 340B covered entities acquire drugs at well below ASP. Community oncology, rheumatology, and other infusion-heavy specialties in 340B programs will see the steepest revenue impact. For a community oncology practice infusing $500,000 per year in 340B-covered drugs, this translates to a six-figure revenue loss in year one if finalized.
CMS proposes expanding site-neutral payment policies to imaging-without-contrast services at off-campus hospital outpatient departments, reducing HOPD payments to the physician payment rate. For practices that bill imaging under HOPD arrangements, this eliminates the HOPD payment premium for these services. Hospital radiology and cardiology departments at off-campus HOPDs are most exposed.
OPPS & ASC Rate Update: 2.4% overall rate increase for non-drug outpatient services. Botulinum Injection Prior Authorization: Beginning July 1, 2027, CMS proposes requiring prior authorization for additional botulinum injection codes in the OPPS setting. Breakthrough Device Pass-Through: The alternative pathway for FDA Breakthrough Devices to qualify for pass-through status is eliminated for applications filed on or after October 1, 2026.
The CY 2027 OPPS comment period closes August 31, 2026. Practices affected by 340B reimbursement changes, imaging site-neutral proposals, or the botulinum injection PA expansion must file comments before that date. Specialty societies (ASCO, ACS, ACC) are coordinating submissions — contact your specialty society this week to align your practice’s comment.
The prior authorization crisis intensified in the first half of 2026. A 31% year-over-year increase in prior authorization denials across commercial and Medicare Advantage payers is documented in current industry tracking, driven by three forces: expanded PA requirement lists following plan contractions, AI-assisted payer adjudication systems making automated upfront rejections, and shortened appeal windows that discourage follow-through.
Of all Medicare Advantage prior authorization denials, only 11.5% are ever appealed — yet when appeals are filed, 80.7% are fully or partially overturned. Payers are collecting denial revenue on claims that, had they been appealed, would have been reversed more than 4 out of 5 times. For a practice receiving 100 MA denials per month, that gap represents approximately 88 unopened appeal opportunities monthly.
Evidence from a 2026 study published in npj Digital Medicine shows that AI-aided payer prior authorization adjudication leads to higher denial rates and larger reductions in healthcare utilization than human-reviewed PA decisions. Payer AI systems now review many requests before physicians do. Beginning in 2026, federal rules require payers to provide a specific reason for any denial regardless of communication channel — a tool practices can use to build more targeted appeals.
The April 2026 CMS proposed rule on drug PA interoperability (CMS-0062-P) would establish 24-hour decision timelines for urgent drug PA requests and 72-hour timelines for standard requests across Medicare, Medicaid, and commercial plans. The comment period closed June 15, 2026. Practices with high-volume infusion, specialty pharmacy, or oncology drug billing should monitor finalization closely.
Pull your last 90 days of MA prior authorization denials and calculate what percentage you appealed. If your appeal rate is below 30%, you are forfeiting recoverable revenue. Implement a systematic denial appeal workflow or evaluate AI-generated appeal tools — the 80.7% overturn rate means the appeal is not a long shot; it is statistically the expected outcome.
The ambient documentation and AI-assisted revenue cycle market crystallized into a two-track race this week. Abridge — named #1 Best in KLAS for Ambient AI two consecutive years — extended its Series E to $316M, backed by Andreessen Horowitz and Khosla Ventures, and announced expanded integration with Availity for real-time prior authorization directly from clinical documentation. Microsoft’s Nuance division earned the top KLAS score in clinical documentation integrity (CDI) and Dragon Medical One ranked highest in front-end EHR speech recognition.
The competitive advantage in 2026 is not which ambient AI captures notes best — it is which platform connects documentation to downstream revenue events: prior authorization, coding, and denial prevention. Abridge’s Availity partnership represents the first real-time ambient-to-PA workflow in production. Microsoft/Nuance’s CDI leadership means documentation gaps are flagged before coding rather than after denials.
The adoption gap between the 63% who have piloted AI and the 15% who have fully integrated it is the central RCM technology challenge of 2026. Practices in the pilot phase that have not defined specific ROI milestones for moving to production are at risk of remaining in perpetual pilot while competitors achieve the collections benefit.
AI sees denial patterns 3 weeks earlier than manual revenue cycle review — enough lead time for corrective action before claim submission. Practices using AI denial prediction before submission rather than after denial achieve fundamentally different economics than those using it only for appeal generation.
The fiscal year 2027 ICD-10-CM code set is finalized. 190+ new codes, 4 revised codes, and 21–30 deleted codes become effective October 1, 2026 — 62 days from today. This is not a minor update: obstetrics, sinusology, and endocrinology each receive clinically meaningful additions that will affect documentation and billing workflows at affected specialty practices.
Obstetrics — Vanishing Twin Pregnancy (O31.4): 33 new codes under category O31.4 for “continuing pregnancy after vanishing twin syndrome.” These codes provide granularity around gestational timing, affected fetus position, and outcome parameters. OB/GYN and maternal-fetal medicine practices should update documentation templates now to capture the specificity these codes require.
ENT / Head & Neck — Odontogenic Sinusitis (J34.83): New codes under J34.83 now require a sixth character specifying the affected sinus (maxillary, ethmoid, frontal, or sphenoid). Practices currently using unspecified sinusitis codes for odontogenic cases risk downcoding on claims submitted after October 1 without the required specificity.
Endocrinology — BMI Underweight (Z68.18 and Z68.19): Two new BMI codes for underweight patients expand the Z68 series. Z68.18 covers BMI 17.0–17.9; Z68.19 covers BMI under 17.0. These are particularly relevant for eating disorder programs, geriatric medicine, and oncology practices where underweight status carries reimbursement and quality measure implications.
July 1, 2026 NCD Update Already Effective (CR 14356): CMS Transmittal MM14356, effective July 1, 2026, implemented National Coverage Determination ICD-10 updates and code revisions. This is already in effect. Practices that have not reviewed the July 1 NCD code updates may have active billing mismatches with coverage determinations.
Practices that do not update EHR templates, superbills, and coder training materials before October 1, 2026 will submit non-compliant claims on day one of the new fiscal year. With 62 days remaining, there is enough time to train and test — but not enough time to procrastinate. Assign code update accountability to a specific team member by end of this week.
The mid-year mark is the right moment to reset revenue cycle benchmarks. Two external pressures make this more urgent than in prior years: the CMS Wasteful and Inappropriate Service Reduction (WISeR) model added prepayment oversight for high-risk procedures in 6 states beginning January 2026, and the combination of MA plan exits, denial rate increases, and October 1 coding changes creates compounding revenue leakage risk through year-end.
| Metric | Excellent | Industry Average | Warning Zone |
|---|---|---|---|
| Days in Accounts Receivable | Under 30 | 30–45 | Over 60 |
| First-Pass Clean Claim Rate | 97%+ | ~95% | Under 90% |
| Denial Rate | Under 3% | 3–5% | Over 8% |
| Cost to Collect | 3–4% | 5–7% | Over 10% |
| Net Collection Rate | 98%+ | 95–97% | Under 92% |
Launched January 15, 2026 in 6 states, WISeR applies prepayment review to procedures CMS has flagged as high-risk for overuse. Affected practices may experience delayed payment on flagged procedure codes. Documentation must be robust enough to withstand prepayment scrutiny — the same clinical documentation improvement tools used for coding quality also harden these claims.
Practices that automate revenue cycle management — eligibility verification, PA submission, claim scrubbing, denial categorization, and payment posting — consistently report 15% or more in net collections increases. The denominator matters: automation both increases collections and reduces cost-to-collect, compressing the ratio in both directions simultaneously.
Two technology developments dominated the RCM vendor landscape this week. First, competitive lines in ambient documentation solidified around two platforms: Abridge for front-end clinical note generation with Epic integration, and Microsoft Nuance for clinical documentation integrity (CDI) and back-end coding quality. Second, the MA plan exit wave has created an underappreciated operational burden: practices need to audit and update provider credentialing in every replacement plan that absorbed a departing insurer’s network.
KLAS awarded Abridge #1 Best in KLAS for Ambient AI in Revenue Cycle Management for the second consecutive year (most recently February 2026), with A+ scores across Culture, Loyalty, Relationship, and Value. Microsoft’s Nuance CDI solution earned the highest points in the clinical documentation integrity category in the same KLAS evaluation period. Dragon Medical One (Nuance’s front-end speech solution) ranked highest for front-end EHR speech recognition.
Abridge’s differentiation is its Availity integration for real-time PA from clinical documentation — closing the ambient-to-authorization workflow gap. Microsoft/Nuance’s differentiation is breadth: CDI, front-end speech, and back-end coding quality as a connected stack with Microsoft Azure as infrastructure. Neither platform owns the full revenue cycle; the practices that achieve the highest ROI will integrate both or select an EHR-native solution that bridges them.
In 2026, UHC exited 109 counties, Humana exited 194 counties across 3 fewer states, and Aetna exited 100 counties in 1 fewer state. Practices in these markets face a credentialing and contracting problem: replacement plans that absorbed displaced enrollees may have different credentialing requirements, different fee schedules, and different provider directory accuracy standards. CMS tightened provider directory rules for 2026–2027. Practices must ensure their credentials are current in every active plan or face network disruption and delayed credentialing claims.
RCM vendors are actively acquiring patient payment companies. Per TechTarget RevCycle reporting, vendor consolidation is narrowing around platforms that can own the full patient-to-payment continuum rather than single-function point solutions. For practices evaluating vendor contracts, this signals that single-vendor RCM platforms will increasingly bundle patient payment, eligibility, coding, and denial management — creating lock-in but also reducing integration friction.
Practices in MA plan exit counties should run a credentialing audit this week: identify every plan that absorbed displaced enrollees in your market, verify your enrollment status and provider directory accuracy in each replacement plan, and confirm your fee schedule terms. Network disruption from credentialing gaps is a silent revenue risk that may not surface until claims reject weeks or months after the plan transition.
Three compliance deadlines and enforcement actions require immediate attention for practices billing in the current regulatory environment.
The comment window for CMS’s CY 2027 OPPS Proposed Rule (CMS-1850-P) closes August 31, 2026 — 31 days from today. Practices affected by 340B drug payment changes, imaging site-neutral proposals, or the botulinum injection PA expansion should file substantive comments. Specialty societies (ASCO, ACS, ACC) are coordinating comment submissions. Aligning your practice’s comment with your specialty society’s filing maximizes CMS responsiveness to specialty-specific concerns.
CMS enforcement of updated Hospital Price Transparency requirements began April 1, 2026. The 2026 OPPS/ASC final rule shifted machine-readable file (MRF) requirements from estimated allowed amounts to actual payment data — a significant accuracy upgrade. Practices affiliated with hospital systems need to confirm their MRF submissions reflect actual negotiated rates, not estimates. Type 2 NPI is now required in general data elements. An Attestation Statement (replacing the prior Affirmation Statement) now requires the name of the Attester.
The 2026 MA plan exit wave displaced approximately 2.9 million enrollees (a 10% forced disenrollment rate) into replacement plans. Practices in affected markets must audit their credentialing status in every replacement plan and verify that provider directory accuracy meets 2026–2027 CMS standards. CMS has tightened oversight and increased downstream consequences for inaccurate or untimely provider data.
| Deadline | Action Required |
|---|---|
| August 31, 2026 | CY 2027 OPPS/ASC comment period closes — submit specialty-specific comments |
| October 1, 2026 | FY 2027 ICD-10-CM codes effective — EHR templates and superbills must be updated |
| January 1, 2027 | CY 2027 PFS effective; ASM mandatory participation begins; new coding policies active |
| July 1, 2027 | Botulinum injection PA requirement begins (if CY 2027 OPPS finalized as proposed) |
If your practice or affiliated health system participates in 340B drug programs, model the revenue impact of the proposed ASP−33.4% reimbursement rate now — before the August 31 comment deadline. Your quantified impact analysis is the most credible content you can include in a CMS comment submission.
The pace of physician practice consolidation reached a new threshold in 2025. According to Becker’s reporting citing AMA and Physicians Advocacy Institute data, 85,000 physician practices were acquired by hospitals and corporate entities between 2018 and 2026. In 2025 alone, 29,600 physicians became hospital employees. Since 2024, 48,100 physicians have left independent practice. As of 2026, approximately 18% of physicians remain in independent or small-group practice — and that cohort faces a convergence of financial pressures that the CY 2027 OPPS proposed rule will worsen.
CMS’s proposed cut of 340B drug reimbursement from ASP+6% to ASP−33.4% was designed partly to reduce hospital system incentives to acquire physician practices in order to extend 340B pricing advantages into those settings. However, critics from the independent practice side argue the proposal removes a cross-subsidization advantage that previously allowed large hospital-affiliated practices to support primary and specialty care — potentially accelerating acquisitions rather than slowing them, as independent practices without 340B access were already operating on thinner margins.
Only 24% of independent physician practices report high or complete visibility into where they are losing revenue. Revenue leakage from MA plan exits, PA denial increases, and coding specificity gaps is particularly difficult for independent practices to identify and address without RCM analytics infrastructure. The practices that remain independent in 2026 and beyond will need RCM intelligence tools that were once only accessible to large health systems.
| Metric | Target | Watch Threshold | Action Trigger |
|---|---|---|---|
| Days in Accounts Receivable | Under 40 days | 45–55 days | Over 55 days — RCM process audit required |
| First-Pass Clean Claim Rate | 96%+ | 92–95% | Under 90% — front-end coding workflow breakdown |
| Denial Rate | Under 5% | 6–8% | Over 8% — root-cause analysis this week |
| Cost to Collect | Under 6% | 7–9% | Over 10% — RCM vendor evaluation needed |
| MA Appeal Rate | Over 30% of MA denials | 15–30% | Under 15% — systematic appeal workflow missing |
The MA appeal rate benchmark deserves special attention: with 80.7% of appealed MA denials overturned, independent practices that appeal fewer than 30% of their MA denials are effectively forfeiting recoverable revenue to the payer. This is the single highest-ROI workflow improvement available to independent practices right now — no technology purchase required.
Advance Care Planning (ACP) billing remains an underutilized revenue opportunity. CPT 99497 (first 30 minutes of ACP discussion) and 99498 (each additional 30 minutes) are reimbursable under Medicare — yet many primary care practices are not systematically billing these codes. Combined with APCM G-codes (live since January 2026), primary care practices should conduct a CPT utilization audit to identify uncaptured ACP and chronic care management revenue before year-end close. | Update: CY 2027 PFS proposed rule continues support for expanded care management billing infrastructure.
The CY 2027 OPPS proposed rule’s imaging site-neutral payment expansion directly affects hospital-affiliated cardiology departments billing cardiovascular imaging under HOPD rates — reduction to physician payment rate is significant. The Ambulatory Specialty Model (ASM) — mandatory for cardiology groups — enters its implementation period January 1, 2027; quality measure tracking and enrollment must be active now. 340B implications: cardiology drug infusions administered at HOPD-affiliated infusion centers face the ASP−33.4% reimbursement cut if finalized. | Update: File OPPS comments before August 31 on both imaging site-neutral and 340B provisions.
The 2026 CPT update tightened documentation requirements for ultrasound guidance codes used in joint injections and aspiration procedures. Orthopedic practices that bill ultrasound guidance without robust real-time documentation of the guidance rationale face increased audit exposure. Fracture treatment coding now requires explicit documentation of whether manipulation was performed and at what stage — the 2026 update draws a sharper line between closed treatment with vs. without manipulation. The CMS 7-day PA decision window is now active for musculoskeletal procedures under MA plans — workflows built around 14-day windows need to be updated. | Update: Review CPT 2026 orthopedic changes with your coding team this week.
The proposed 340B cut from ASP+6% to ASP−33.4% is the most consequential single regulatory event for community oncology in a generation. Independent oncology practices that rely on 340B drug margin to offset low professional fee reimbursement face an existential margin threat if this is finalized. Community oncology advocates from ASCO and independent practice groups are coordinating comments before August 31. Every community oncology practice should model their 340B drug revenue exposure now and prepare scenario budgets for the 2027 finalized rule. | Update: Contact ASCO for coordinated comment language before August 31.
80 new ICD-10-PCS codes became effective April 1, 2026 — primarily in the New Technology section, including gastrointestinal inspection procedures. GI practices billing hospital outpatient procedures need to verify correct code mapping and confirm these are reflected in their EHR and billing system. The GI Medicare Value Pathways (MVP) quality measures for 2026 are rolling out — GI practices in MIPS tracks should confirm MVP measure selection aligns with their procedure volume mix. | Update: AGA reimbursement resources at gastro.org provide specialty-specific coding guidance.
The CY 2027 PFS proposed rule includes permanent removal of geographic restrictions on behavioral and mental health telehealth and permanent coverage of audio-only visits for behavioral health — a structural revenue expansion for psychiatry, psychology, and mental health practices. This means practices can build sustainable hybrid care models without waiting for PHE extensions. The proposed 24-hour urgent drug PA decision window under CMS-0062-P also benefits practices prescribing mental health medications through Medicaid. | Update: Begin modeling the telehealth revenue impact for CY 2027 now.
The WISeR model, effective January 2026 in 6 states, covers certain neurology procedures flagged as high-risk for overuse under CMS’s prepayment review criteria. Neurology practices in affected states should identify which procedure codes are flagged and ensure documentation proactively addresses medical necessity criteria in a way that withstands prepayment review — not just post-payment audit. | Update: Check CMS WISeR model documentation for the current list of flagged neurology procedure codes.